Cullinan Therapeutics, Inc. 股價、新聞與催化劑

股票表現

股價為何變動

As of Aug 21, 2026, CGEM closed up 1.40% at $21.68. No new same-company headline was identified in the current news window.

公司概覽

未來催化劑

• Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
• Multi-dose rheumatoid-arthritis data for CLN-978 in the third quarter of 2026.
• Additional clinical data for velinotamig during 2026.
• PDUFA target action date for zipalertinib on February 27, 2027.

近期新聞

1. 01
   2026-08-06 11:00 EST

   Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

2. 02
   2026-07-28 11:00 EST

   Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

3. 03
   2026-06-10 11:30 EST

   Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

4. 04
   2026-06-06 09:15 EST

   Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

5. 05
   2026-05-26 11:00 EST

   Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。